Abiopharma

FDA has placed Phase 3 studies of tolebrutinib in multiple sclerosis (MS) and myasthenia gravis on partial clinical hold. The FDA action was based on a limited number of cases of drug-induced liver injury. The majority of the impacted patients were determined to have concurrent complications.